BridgeBio is significantly boosted its progress of an innovative therapy for cardiac amyloidosis, employing the compound. Initial clinical data suggests significant improvements for patients diagnosed with a https://biotech217722.full-design.com/bridgebio-progresses-attr-cm-treatment-with-the-therapy-84783335